OPSUMIT® (macitentan) efficacy
OPSUMIT® is a foundation for pulmonary arterial hypertension (PAH) treatment, and is recommended in first line as monotherapy as well as in combination therapy. The efficacy of OPSUMIT® is demonstrated in the SERAPHIN, OPTIMA and REPAIR trials, while the large real-world OPUS registry and OrPHeUS study show that OPSUMIT® is used effectively in a broad range of patients with PAH.
The SERAPHIN trial assessed the long-term efficacy of OPSUMIT® in a broad range of patients with PAH.
The OPTIMA trial explored the benefits of initial combination therapy with OPSUMIT® and tadalafil in patients with PAH.
The REPAIR trial evaluated the effect of OPSUMIT® on right ventricular structure and function vs baseline.
The OPUS registry and OrPHeUS study demonstrate effective use of OPSUMIT® in the real world.
The potential of OPSUMIT® in REPAIR
Explore this immersive 3D environment to delve deeper into PAH and explore the potential of OPSUMIT® as shown in the REPAIR trial.
PAH, pulmonary arterial hypertension
OPSUMIT® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING
CP-220224 | June 2021
